Cibus, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Cibus reported Q2 2026 net loss of $22.1M (vs. $26.6M YoY); quarterly net cash usage declined 19% sequentially and 31% YoY to ~$20.9M for H1 2026. Company expects ~$35M annual run-rate cash burn exiting 2026. Cash position $20.4M as of June 30, 2026, sufficient through early Q1 2027. Key developments: EU and Ecuador/Peru regulatory approvals treating gene-edited crops (no foreign DNA) as conventionally bred; Rice weed-management traits (HT1/HT3) advancing with customers Interoc and Fedearroz targeting 2028 LATAM launch; Sustainable Ingredients program generating revenue with $20–40M peak opportunity; Interoc letter of intent expanded from 2 to 5 Rice traits. CEO Craig Wichner appointed June 8, 2026. Company has $253.5M royalty liability to related parties (accruing $9.5M quarterly non-cash interest expense).
Why this rating
Cost control and regulatory wins are positive; however, minimal revenue ($2.7M H1 2026), $20.4M cash, and $35M annual burn rate mean ~7 months' runway without new financing. Company remains pre-commercial; near-term funding risk and execution dependence outweigh regulatory progress. Moderate event for $47M market-cap company.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.